Migraine medicine RELPAX recalled over potential microbiological contamination concerns
Pfizer Inc. has issued a recall of 40 mg tablets of RELPAX (eletriptan hydrobromide). RELPAX is us used to treat migraines with or without auras in adults. The lots recalled are AR5407 and CD4565. Pfizer conducts their own in-house testing for the “potential presence of Genus Pseudomonas and Burkholderia” and the testing of these lots “may not meet” their standards. The recalled tablets were distributed to retailers throughout the United States and Puerto Rico from June 2019 - July 2019.
While the likelihood of medical issues from consumption of microorganisms is minimal for most of the population, the U.S. Food and Drug Administration notes that “for certain vulnerable patient populations (such as patients with compromised immune systems, cystic fibrosis and chronic granulomatous disease) there may be the potential for serious adverse events, including life- threatening infections.”
0049-2340-45 AR5407 Expires 2022 FEB 40 mg
Carton containing 6 tablets (1 blister card x 6 tablets)
0049-2340-45 CD4565 Expires 2022 FEB 40 mg
Carton containing 12 tablets (2 blister cards x 6 tablets)
If you believe you’ve been prescribed the recalled medications, you’re encouraged to reach out to your healthcare provider or pharmacy to verify if your lot has been recalled. Customers with questions can contact Pfizer directly at 1-800-438-1985 (option 3). To report any adverse reactions to the drug, you can reach Pfizer at 1-800-438-1985 (option 1).
To read the full recall report from the FDA, click here: https://bit.ly/2ZdCRka